Email Us
Call Us
AUSTIN, Texas – November 15, 2016 – Altogen in vivo delivery technology appears among the citations supporting Nature Communications research into microRNA-mediated chromatin remodelling in diabetic nephropathy, extending the documented use of the platform into renal and metabolic disease research.
Diabetic kidney disease is a leading cause of end-stage renal failure worldwide, and preclinical progress depends on the ability to modulate specific regulatory RNAs in kidney tissue in living animals. Renal delivery presents its own obstacles — rapid clearance, nuclease degradation, and limited tissue penetration — and reproducible results in this setting reflect a well-characterized delivery system rather than a fortunate experiment.
Altogen Labs provides the corresponding contract research capability to sponsors working in nephrology, endocrinology, and metabolic disease. Services include in vivo siRNA and microRNA delivery with tissue targeting, biodistribution and accumulation quantification, target engagement confirmation at both mRNA and protein levels, histopathology and immunohistochemistry of collected tissues, and full in vivo toxicology assessment.
The company’s safety toxicology portfolio covers acute, sub-chronic, and chronic study designs, in vivo LD50 determination in mice and rats, and OECD-guideline testing including acute oral toxicity, repeated-dose oral toxicity, dermal toxicity and irritation, inhalation toxicity, toxicokinetics, chronic toxicity, and carcinogenicity protocols.
Altogen Labs has performed preclinical contract research continuously since 2009 from its GLP-compliant, IACUC-regulated facility in Austin, Texas, supporting sponsors from initial study design through patent filing and regulatory submission.
About Altogen Labs Altogen Labs is a professional, experienced, and highly reputable GLP-compliant contract research organization providing preclinical research and biology CRO services worldwide, offering a large collection of in-house validated xenograft models and extensive experience in efficacy xenograft studies and safety toxicology studies.
Contact Information: Altogen Labs | 11200 Menchaca Rd, Bldg 2, Suite 203 | Austin, TX 78748 USA Tel: 512-433-6177 | Email: info@altogenlabs.com | Web: altogenlabs.com
Source citation: Badal SS, et al., “miR-93 regulates Msk2-mediated chromatin remodelling in diabetic nephropathy,” Nature Communications, 2016